Monitor the integration of the ASK Pharm collaboration and execution of the Singapore redomiciliation, as these could significantly impact the company's valuation and regulatory standing. The reduced R&D spending may impact future pipeline development.
Price Chart
Executive Summary
Adlai Nortye Ltd. reported a reduced net loss of $35.5 million in 2025, driven by lower R&D and administrative expenses, while securing a $230 million collaboration deal for AN9025 and raising $140 million in private financing. The company also announced a proposed redomiciliation to Singapore and made key executive appointments.
Key Facts
- Net loss decreased to $35.5 million in 2025 from $51.9 million in 2024
- R&D expenses decreased 26.9% to $32.8 million in 2025
- Secured $230 million collaboration deal with ASK Pharm for AN9025 in China
- Raised $140 million in private financing
- Proposed redomiciliation from Cayman Islands to Singapore
- Appointed Archie Tse as President and Dr. Ye as CFO
Financial Impact
Reduced net loss of $35.5 million in 2025 with $230 million in potential future payments from collaboration deal
Risk Factors
- Working capital deficiency as of December 31, 2025
- Dependence on future regulatory approvals for pipeline candidates
- Uncertainty around Singapore redomiciliation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-042520 |
| Document: ea028259301ex12-2.htm | 0001213900-26-042520 |
| Document: ea028259301ex12-1.htm | 0001213900-26-042520 |
| Document: ea028259301ex13-2.htm | 0001213900-26-042520 |
| Document: ea028259301ex13-1.htm | 0001213900-26-042520 |
| Document: ea028259301ex15-2.htm | 0001213900-26-042520 |
| Document: ea028259301ex15-1.htm | 0001213900-26-042520 |
| Document: 0001213900-26-042520-index-headers.html | 0001213900-26-042520 |
| Document: 0001213900-26-042520-index.html | 0001213900-26-042520 |
| Document: 0001213900-26-042520.txt | 0001213900-26-042520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Oct 15, 2026 12d ago | Press Release | $12.09 $10.58 | ▼ −12.49% | ▼ −11.48% | $10.71 (−11.41%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 30, 2026 27d ago | 6-K | $16.00 $14.05 | ▼ −12.19% | ▼ −14.10% | $10.71 (−33.06%) |
Sep 16, 2026 5w ago | EFFECT | $15.52 $15.75 | ▲ +1.48% | ▼ −0.34% | $10.71 (−30.99%) |
Aug 26, 2026 8w ago | 6-K | $15.06 $13.86 | ▼ −8.00% | ▼ −7.88% | $10.71 (−28.88%) |
Aug 19, 2026 9w ago | 6-K | $14.33 $15.06 | ▲ +5.09% | ▲ +5.48% | $10.71 (−25.26%) |
Aug 14, 2026 10w ago | 6-K | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 14, 2026 10w ago | Press Release | $13.25 $13.70 | ▲ +3.40% | ▲ +4.76% | $10.71 (−19.17%) |
Aug 3, 2026 12w ago | 6-K | $12.99 $13.23 | ▲ +1.85% | ▼ −0.18% | $10.71 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers